Current controversies and advances in the management of pancreatic adenocarcinoma

Table 6 Treatment protocols for pancreatic adenocarcinoma in adjuvant setting

Drug	Dose and route	Administration	Toxicity
Adjuvant gemcitabine (cycle length: 4 wk)[156]
Gemcitabine	1000 mg/m2 IV	Weekly (× 3 wk) followed by one week of rest	Myelotoxicity; Hepatotoxicity; Pulmonary toxicity; Thrombotic microangiopathy
Adjuvant gemcitabine plus capecitabine (GemCap; cycle length: 28 d)[157]
Gemcitabine	1000 mg/m2 IV	Given on days 1, 8, and 15	Myelotoxicity; Nonhematologic toxicity (including hepatoxicity); Pulmonary toxicity; Thrombotic microangiopathy
Capecitabine	830 mg/m2 per dose by mouth	Given on days 1 through 21
Modified FOLFIRINOX (cycle length: 14 d)[158-162]
Oxaliplatin	85 mg/m2 IV	Given on day 1	Myelotoxicity; Diarrhea; Mucositis or hand-foot syndrome; Pulmonary toxicity; Neurotoxicity; Cardiotoxicity
Leucovorin	400 mg/m2 IV	Given on day 1
Irinotecan	150 mg/m2 IV	Given on day 1
Fluorouracil	2400 mg/m2 IV	Given on day 1